Skip to content

Home
>Resources

Discover How Helix is Changing the World of Healthcare

Resources Hub

The Latest Content From Helix

Recent Blog Posts

View All Blog Posts

Partnering with Veracyte to Deliver More Complete Genomic Insights in Prostate Cancer Care

From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.

By James Lu, MD, PhD, CEO and Co-Founder of Helix

Understanding Hidden Heart Risk: How Genetics Can Inform Your Lp(a) Levels

GLP-1 Spending Is Spiraling — But There's a Smarter Way Forward

Recent Press Releases

View All Press Releases

Parkview expands DNA Insights program to the public

September 9, 2025

Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care

Helix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s Treatments

Recent Videos

View All Videos

Partner Perspectives with Nebraska Medicine

Genetic Insights Project helps Nebraskans take charge of their health

Partner Perspectives with MUSC - Update

Revolutionizing Healthcare: In Our DNA SC

Partner Perspectives with Renown Health - Update

The Healthy Nevada Project - update 2023

Recent Published Research

View All Published Research

1

Published Research

From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence

August 15, 2025

2

Published Research

Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort

3

Published Research

Chatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering Project

4

Published Research

Individuals with PMS2 pathogenic variants are at average risk of cancer before age 60

5

Published Research

Scalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions

Recent Whitepapers

View All Whitepapers

Performance and Applications of Helix Exome+^® Assay

October 7, 2024

White Paper: Semaglutide and Weight Management

Technical Briefing 6: JN.1

January 3, 2024

Technical Briefing 5: SARS-CoV-2 Antiviral Treatment Gaps

October 11, 2023

The Latest Content From Helix

Recent Blog Posts

View All Blog Posts

Partnering with Veracyte to Deliver More Complete Genomic Insights in Prostate Cancer Care

From Niche to Necessity: Precision Medicine Isn’t an Initiative. It’s the New Infrastructure.

By James Lu, MD, PhD, CEO and Co-Founder of Helix

Understanding Hidden Heart Risk: How Genetics Can Inform Your Lp(a) Levels

GLP-1 Spending Is Spiraling — But There's a Smarter Way Forward

Recent Press Releases

View All Press Releases

Parkview expands DNA Insights program to the public

September 9, 2025

Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care

Helix Expands Pharmacogenomic Test Portfolio to Support Safer Cancer and Alzheimer’s Treatments

Recent Videos

View All Videos

Partner Perspectives with Nebraska Medicine

Genetic Insights Project helps Nebraskans take charge of their health

Partner Perspectives with MUSC - Update

Revolutionizing Healthcare: In Our DNA SC

Partner Perspectives with Renown Health - Update

The Healthy Nevada Project - update 2023

Recent Published Research

View All Published Research

1

Published Research

From Uncertain to Actionable: Significant Reduction in Variants of Uncertain Significance in Hereditary Germline Testing via Multi-Institutional Real-World Evidence

August 15, 2025

2

Published Research

Novel Method for Predicting Lp(a) From Genomic Testing Identifies ASCVD Risk Across a Diverse Cohort

3

Published Research

Chatbot for the Return of Positive Genetic Screening Results for Hereditary Cancer Syndromes: Prompt Engineering Project

4

Published Research

Individuals with PMS2 pathogenic variants are at average risk of cancer before age 60

5

Published Research

Scalable system-wide CYP2C19 pharmacogenomic testing reveals 38% excess incidence of adverse events in metabolizers receiving inappropriate prescriptions

Recent Whitepapers

View All Whitepapers

Performance and Applications of Helix Exome+^® Assay

October 7, 2024

White Paper: Semaglutide and Weight Management

Technical Briefing 6: JN.1

January 3, 2024

Technical Briefing 5: SARS-CoV-2 Antiviral Treatment Gaps

October 11, 2023

Get in touch